Avalus Ultra Post-Approval Study (PAS)
NCT06506903
Recruiting
The purpose of this study is to characterize the safety and effectiveness of the Medtronic Avalus Ultra aortic valve bioprosthesis in patients with aortic valve disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Hartford Hospital, Hartford, Connecticut +11 locations
Conditions: Aortic Valve Disease
Register for Updates
ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
NCT06597721
Recruiting
Adcendo ApS is conducting a phase 1 study of an investigational drug called ADCE-T02 (previously known as AMT-754), a tissue factor targeted antibody-drug conjugate which may be used in the future as a possible treatment for advanced solid tumors. The main purpose of the study is to determine the Maximum Tolerated Dose (MTD), the recommended dose and the safety and tolerability of ADCE-T02 when given as a single therapy over a range of different dose levels.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: MD Anderson Cancer Center, Houston, Texas +5 locations
Conditions: Advanced Solid Tumor
Register for Updates
A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)
NCT06687980
Recruiting
This is a parallel, Phase 3, 2-arm study for treatment. The purpose of this study is to measure improvement in pruritus with dupilumab subcutaneous injections compared with placebo injections in male and female participants aged at least 18 years with LSC. Study details include: The study duration will be up to 40 weeks. The treatment duration will be up to 24 weeks. The follow-up duration after treatment will be 12 weeks. The number of visits will be 6.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Center for Dermatology Clinical Research- Site Number : 8400226, Fremont, California +46 locations
Conditions: Lichen Simplex Chronicus
Register for Updates
CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation
NCT06762964
Recruiting
The purpose of this research is to determine whether treatment with the study drug dapagliflozin for 6 months affects pulmonary capillary wedge pressure (PCWP) at rest and during exercise in adults with failing Fontan circulation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Fontan Circulation, Single Ventricle Heart Disease, HFpEF - Heart Failure with Preserved Ejection Fraction
Register for Updates
A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)
NCT06941844
Recruiting
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Major Depressive Disorder - Emerge
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
05/19/2025
Locations: Preferred Research Partner, Fayetteville, Arkansas +25 locations
Conditions: Major Depressive Disorder
Register for Updates
Thinking Zinc: a Study of Zinc Supplements on the Navajo Nation
NCT03908736
Recruiting
This is a study to assess the effect of dietary zinc supplementation to mitigate biomarkers of metal toxicity in exposed tribal populations.
Gender:
ALL
Ages:
Between 21 years and 64 years
Trial Updated:
05/19/2025
Locations: University of New Mexico Health Sciences Center, Albuquerque, New Mexico
Conditions: DNA Damage, Immune System Disorder
Register for Updates
A Randomized Control Trial of Motor-based Intervention for CAS
NCT04642053
Recruiting
Childhood apraxia of speech (CAS) is a complex, multivariate speech motor disorder characterized by difficulty planning and programming movements of the speech articulators (ASHA, 2007; Ayres, 1985; Campbell et al., 2007; Davis et al., 1998; Forrest, 2003; Shriberg et al., 1997). Despite the profound impact that CAS can have on a child's ability to communicate, little data are available to direct treatment in this challenging population. Historically, children with CAS have been treated with art... Read More
Gender:
ALL
Ages:
Between 29 months and 95 months
Trial Updated:
05/19/2025
Locations: New York University, Department of Communicative Sciences & Disordesr, New York, New York
Conditions: Childhood Apraxia of Speech
Register for Updates
Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
NCT05168930
Recruiting
This study is being done to test the effectiveness of zanubrutinib in combination with venetoclax in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: New England Cancer Specialists, Scarborough, Maine +3 locations
Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Register for Updates
Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy
NCT05472792
Recruiting
The aim of this prospective study is to investigate quality of life and oncologic outcomes in low-risk elderly breast cancer patients randomized to adjuvant therapy with accelerated partial breast irradiation (APBI) alone or endocrine therapy alone after lumpectomy. The study population will include women age 65 years and older with low-risk tumor characteristics (tumor size \<2cm, grade 1-2, node-negative). APBI will consist of 5 fractions of radiation therapy delivered every other day to the l... Read More
Gender:
FEMALE
Ages:
65 years and above
Trial Updated:
05/19/2025
Locations: University of North Carolina, Chapel Hill, North Carolina
Conditions: Breast Cancer, Quality of Life
Register for Updates
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
NCT05746559
Recruiting
The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the clinical consequences of AKI (MAKE) at 90 days in adult participants with CKD who undergo non-emergent cardiac surgery with CPB.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
05/19/2025
Locations: Research Site, Tucson, Arizona +214 locations
Conditions: Chronic Kidney Disease, CKD, Cardiac Disease, Cardiopulmonary Bypass
Register for Updates
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis
NCT06046222
Recruiting
This study will enroll male and female subjects who are 18 years of age or older with Eosinophilic Granulomatosis With Polyangiitis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: National Jewish Health, Denver, Colorado +33 locations
Conditions: Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome
Register for Updates
ZILRETTA in Subjects With Shoulder Osteoarthritis
NCT06269705
Recruiting
Primary Objective: To assess the efficacy of ZILRETTA on pain following an intra-articular (IA) injection in subjects with glenohumeral osteoarthritis (OA) relative to normal saline placebo Secondary Objective: * To assess the efficacy of ZILRETTA on pain following an IA injection in subjects with glenohumeral OA relative to triamcinolone acetonide injectable suspension, immediate release (TCA-IR) and normal saline placebo * To assess the safety of ZILRETTA in subjects with glenohumeral OA rel... Read More
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
05/19/2025
Locations: Alabama Orthopaedic Center- Research, Vestavia Hills, Alabama +31 locations
Conditions: Glenohumeral Osteoarthritis
Register for Updates